Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5926-5930. doi: 10.1016/j.bmcl.2016.10.092. Epub 2016 Nov 2.

Abstract

Herein, we describe the synthesis of Pyk2 inhibitors via macrocyclization of FAK and dual Pyk2-FAK inhibitors. We identified macrocycle 25a as a highly potent Pyk2 inhibitor (IC50=0.7nM), with ∼175-fold improvement in Pyk2 potency as compared to its acyclic counterpart. In many cases, macrocyclization improved Pyk2 potency while weakening FAK potency, thereby improving the Pyk2/FAK selectivity ratio for this structural class of inhibitors. Various macrocyclic linkers were studied in an attempt to optimize Pyk2 selectivity. We observed macrocyclic atropisomerism during the synthesis of 19-membered macrocycles 10a-d, and successfully obtained crystallographic evidence of one atropisomer (10a-AtropB) preferentially bound to Pyk2.

Keywords: Atropisomer; FAK; Glioblastoma; Macrocycle; Pyk2.

MeSH terms

  • Animals
  • Cyclization
  • Dogs
  • Dose-Response Relationship, Drug
  • Focal Adhesion Kinase 2 / antagonists & inhibitors*
  • Focal Adhesion Kinase 2 / metabolism
  • Humans
  • Macromolecular Substances / chemical synthesis
  • Macromolecular Substances / chemistry
  • Macromolecular Substances / pharmacology
  • Mice
  • Models, Molecular
  • Molecular Structure
  • Protein-Tyrosine Kinases / chemical synthesis
  • Protein-Tyrosine Kinases / chemistry
  • Protein-Tyrosine Kinases / pharmacology*
  • Structure-Activity Relationship

Substances

  • Macromolecular Substances
  • Protein-Tyrosine Kinases
  • Focal Adhesion Kinase 2